Journal of Hematology & Oncology | Therapeutic Evolution and Future Directions of PD-L1-Targeted Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

This study systematically reviews clinical evidence of immunotherapy for NSCLC from advanced to early-stage disease, providing critical insights for designing personalized immunotherapy strategies based on PD-L1 expression and tumor microenvironment characteristics. It offers significant guidance for exploring combination therapies and developing biomarkers.

 

Literature Overview

The article 'Current and future immunotherapies for NSCLC,' published in the Journal of Hematology & Oncology, systematically explores the clinical advancements of immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC), covering multidimensional strategies from first-line treatment in advanced disease to perioperative interventions in early stages. The article reviews the biological basis of the PD-1/PD-L1 and CTLA-4 pathways, summarizes data from pivotal Phase III clinical trials, and deeply analyzes current challenges in treatment, such as resistance mechanisms, biomarker optimization, and toxicity management. Furthermore, the authors discuss next-generation immunotherapies—including bispecific antibodies, mRNA vaccines, and cell therapies—providing a clear roadmap for future research.

Background Knowledge

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths worldwide. Although targeted therapies and immunotherapies have significantly improved outcomes for some patients, most still face primary or acquired resistance. Currently, PD-1/PD-L1 pathway blockade has become the standard first-line treatment for NSCLC without driver gene mutations, but its efficacy is limited by the imperfect predictive accuracy of PD-L1 expression alone. Emerging biomarkers such as tumor mutational burden (TMB), microsatellite instability (MSI), and dynamic ctDNA changes are being explored to improve patient selection. Additionally, co-mutations such as KRAS with STK11 or KEAP1 have been shown to correlate with resistance to immunotherapy, suggesting that intrinsic tumor signaling pathways regulate the immune microenvironment. Therefore, integrating multi-parameter models to precisely identify responsive populations and overcome immune escape mechanisms has become a central challenge in current research. This review addresses these issues by systematically integrating existing clinical evidence and cutting-edge scientific discoveries, proposing a paradigm shift from monotherapy to combination regimens, from advanced to early-stage disease, and from empirical to biomarker-driven treatment, offering a theoretical framework to tackle the aforementioned challenges.

 

 

Research Methods and Experiments

The authors employed a narrative review approach, systematically retrieving and synthesizing data from key randomized controlled trials (RCTs) published up to 2026, including the CheckMate, KEYNOTE, IMpower, and AEGEAN trial series. By comparing the efficacy and safety of different strategies—such as ICI monotherapy, ICI-chemotherapy combinations, dual immunotherapy, and perioperative regimens—across disease stages, they constructed a comprehensive landscape of NSCLC immunotherapy. Particular attention was paid to the impact of PD-L1 expression levels (TPS ≥1%, ≥20%, ≥50%) on treatment selection, and the potential value of emerging biomarkers such as ctDNA clearance, TCR clonal expansion, and gut microbiome composition was analyzed in depth. Additionally, the authors evaluated early clinical data from novel therapeutic strategies, including bispecific antibodies targeting PD-1 and LAG-3, personalized mRNA vaccines combined with ICIs, and the potential applications of antibody-drug conjugates (ADCs) and cell therapies (e.g., CAR-T).

Key Conclusions and Perspectives

• ICI monotherapy significantly prolongs OS in NSCLC patients with high PD-L1 expression (≥50%), but cross-trial comparisons are limited by population heterogeneity, and patients with low expression derive limited benefit, indicating the need for more precise PD-L1 testing standards and complementary biomarkers.
• Combining chemotherapy with ICIs significantly improves PFS and OS across all PD-L1 subgroups, making it the preferred regimen for patients with PD-L1<1%, although increased toxicity necessitates careful balancing of patient tolerance and long-term survival benefits.
• Dual immunotherapy (e.g., nivolumab + ipilimumab) offers a chemotherapy-free option, but the high incidence of irAEs—particularly immune-mediated pneumonitis in NSCLC patients—requires close monitoring, highlighting the need for optimized patient selection and toxicity management strategies.
• Perioperative immunotherapy (e.g., AEGEAN, NADIM II) significantly improves pCR and EFS, supporting its use in resectable stage III NSCLC; however, the optimal treatment duration (number of neoadjuvant cycles) and whether adjuvant maintenance is necessary remain to be determined, requiring individualized perioperative ICI strategies.
• Dynamic ctDNA monitoring can enable early prediction of recurrence and treatment response; ctDNA clearance may serve as a surrogate endpoint to accelerate drug development, facilitating a shift toward real-time, biomarker-driven adaptive treatment models.
• The gut microbiome influences ICI efficacy; microbiome composition could serve as an actionable predictive factor, and future interventions such as fecal microbiota transplantation or probiotics may enhance anti-tumor immune responses.
• Next-generation therapies such as mRNA vaccines and bispecific antibodies show promise in early studies, but larger trials are needed to confirm their role in overcoming primary resistance.

Research Significance and Prospects

This study provides clear direction for drug development: future efforts should focus on developing multi-target combination strategies to overcome resistance, such as bispecific antibodies targeting PD-1 and TIGIT or TIM-3. In terms of clinical monitoring, dynamic ctDNA testing may guide individualized treatment duration decisions, reducing unnecessary toxic exposure. Additionally, using organoid or PDX models for drug sensitivity testing, combined with immune profiling, could enhance the predictive power of disease modeling and accelerate translational research.

 

 

Conclusion

This review comprehensively summarizes the current state and future directions of immunotherapy in NSCLC, emphasizing the transition from a one-size-fits-all approach to a more precise and personalized treatment paradigm. Although PD-1/PD-L1 inhibitors have significantly improved patient survival, primary and acquired resistance remain major obstacles. Integrating multi-dimensional data—including PD-L1, TMB, ctDNA, and microbiome profiles—holds promise for more accurate patient stratification. Breakthroughs in perioperative immunotherapy offer curative potential for early-stage patients, while novel therapies such as bispecific antibodies, mRNA vaccines, and cell therapies are reshaping the treatment landscape. Future research must optimize safety while maintaining efficacy, explore de-escalation strategies, and establish dynamic monitoring systems. Ultimately, these advances will shift NSCLC from an 'incurable' to a 'chronic controllable' disease, offering patients worldwide longer survival and improved quality of life. This study provides a solid foundation for translational research between the laboratory and clinic, with profound implications for biomarker validation and the design of novel therapeutic combinations.

 

Chu-Yu Zhou, Yi-Fan Qi, Hong-Ji Li, Mei-Mei Zheng, and Wen-Zhao Zhong. Current and future immunotherapies for NSCLC. Journal of Hematology & Oncology.